McMillan Office’s Avanos Medical AVNS Stock Holding History

McMillan Office’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.82K	Sell	701 -149	-18%	-$2.01K	﹤0.01%	389
2025 Q4	$9.55K	Buy	+850	New	+$9.73K	﹤0.01%	386

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

McMillan Office's AVNS Position: Q1 2026 in Review

McMillan Office reduced its Avanos Medical (AVNS) stake by 18% in Q1 2026, selling an estimated $2.01K and leaving 701 shares worth $9.82K. The position accounts for ﹤0.01% of the portfolio, ranked #389.

McMillan Office first reported a position in AVNS in Q4 2025 and has held it in 2 quarters since. 257 funds tracked by Wall St. Rank hold AVNS as of Q1 2026.

McMillan Office held 701 shares of Avanos Medical worth $9.82K as of Q1 2026.
McMillan Office sold 149 Avanos Medical shares in Q1 2026, an estimated $2.01K.
Avanos Medical made up ﹤0.01% of McMillan Office's portfolio in Q1 2026, its #389 holding.
McMillan Office first reported a position in Avanos Medical in Q4 2025 and has held it in 2 quarters since.
257 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2026.

Based on McMillan Office's 13F filing for Q1 2026, filed 23 Apr 2026.